REGN News and Press, Regeneron Pharmaceuticals Inc. From 06/12/24

2024-06-12 09:00:07 ET Brian Abrahams from RBC Capital issued a price target of $1,229.00 for REGN on 2024-06-12 07:24:00. The adjusted price target was set to $1,229.00. At the time of the announcement, REGN was trading at $1010.54. The overall price target consensus is...

A look at the top 10 most actives in the United States Nauticus Robotics Inc. (KITT) rose 16.9% to $0.27 on volume of 539,575,904 shares Trio Petroleum Corp. (TPET) rose 56.3% to $0.3596 on volume of 234,580,380 shares NVIDIA Corporation (NVDA) fell 0.7% to $120.91 on volume of 221,192,27...

2024-06-11 14:46:20 ET More on Regeneron Pharmaceuticals Regeneron Pharmaceuticals, Inc. (REGN) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript) Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Tran...

2024-06-11 10:07:05 ET Regeneron Pharmaceuticals, Inc. (REGN) Goldman Sachs 45th Annual Global Healthcare Conference June 11, 2024, 08:00 AM ET Company Participants Ryan Crowe - Head of IR Chris Fenimore - CFO Conference Call Participants Salveen Richter ...

2024-06-11 07:49:42 ET More on Sanofi, Regeneron, etc. Regeneron Pharmaceuticals, Inc. (REGN) Management presents at Jefferies 2024 Global Healthcare Conference (Transcript) Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript) ...

2024-06-10 20:52:27 ET The biotech sector includes companies that develop drugs and diagnostic technologies based on biology. These firms often focus on developing innovative treatments for various medical conditions. Investments in this sector are driven by the potential for significant br...

2024-06-07 10:10:00 ET Stock splits are back in style. Over the past few months, both fast-casual chain Chipotle and chip giant Nvidia announced plans to split their stocks. There's no knowing for sure if more such announcements are on the horizon -- but shares of some top companies...

2024-06-06 12:38:52 ET Summary FibroGen, Inc. top-line data from the phase 2/3 PanCAN Precision Promise study, using pamrevlumab for the treatment of patients with metastatic pancreatic cancer, expected mid-2024. Topline data from the phase 3 LAPIS study, using pamrevlumab for the...

2024-06-06 10:47:18 ET More on 2seventy bio 2seventy bio, Inc. (TSVT) Q1 2024 Earnings Call Transcript 2seventy Bio: Maximizing ABECMA's Potential To Fuel A Turnaround Bristol-Myers posts Q1 beat despite growth headwinds Bristol Myers, 2seventy bio's Abecma a...

2024-06-06 09:07:10 ET Summary AstraZeneca PLC showcased projects in two plenary lecture presentations at the Annual Meeting of the American Society of Clinical Oncology, or ASCO, including a trial that established osimertinib as the standard of care for EGFR-mutant NSCLC. Bristol...